Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD
- 10 February 2011
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 117 (6), e67-e74
- https://doi.org/10.1182/blood-2010-08-299016
Abstract
Von Willebrand disease (VWD) is a common bleeding disorder, but diagnosis is sometimes challenging because of issues with the current von Willebrand factor (VWF) assays, VWF antigen (VWF:Ag) and VWF ristocetin cofactor activity (VWF:RCo), used for diagnosis. We evaluated 113 healthy controls and 164 VWD subjects enrolled in the T.S. Zimmerman Program for the Molecular and Clinical Biology of VWD for VWF:Ag, VWF:RCo, and a new enzyme-linked immunosorbent assay (ELISA)–based assay of VWF-glycoprotein Ib (GPIb) interactions using a gain-of-function GPIb construct (tGPIbα235Y;239V) as a receptor to bind its ligand VWF in an assay independent of ristocetin (VWF:IbCo ELISA). Healthy controls, type 1, 2A, 2M, and 2N subjects had VWF:RCo/VWF:Ag ratios similar to the ratio obtained with VWF:IbCo ELISA/VWF:Ag. Type 2B VWD subjects, however, had elevated VWF:IbCo ELISA/VWF:Ag ratios. Type 3 VWD subjects had undetectable (< 1.6 U/dL) VWF:IbCo ELISA values. As previously reported, VWF:RCo/VWF:Ag ratio was decreased with a common A1 domain polymorphism, D1472H, as was direct binding to ristocetin for a 1472H A1 loop construct. The VWF:IbCo ELISA, however, was not affected by D1472H. The VWF:IbCo ELISA may be useful in testing VWF binding to GPIb, discrimination of type 2 variants, and in the diagnosis of VWD as it avoids some of the pitfalls of VWF:RCo assays.This publication has 52 references indexed in Scilit:
- Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactorBlood, 2010
- Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWDJournal of Thrombosis and Haemostasis, 2010
- An Update on the von Willebrand Factor Collagen Binding Assay: 21 Years of Age and Beyond Adolescence but Not Yet a Mature AdultSeminars in Thrombosis and Hemostasis, 2007
- Challenges in defining type 2M von Willebrand disease: results from a Canadian cohort studyJournal of Thrombosis and Haemostasis, 2007
- The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort studyBlood, 2007
- The A/T1381 polymorphism in the A1-domain of von Willebrand factor influences the affinity of von Willebrand factor for platelet glycoprotein IbαThrombosis and Haemostasis, 2007
- Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survivalBlood, 2006
- External Peer Review Quality Assurance Testing in von Willebrand Disease: The Recent Experience of the United States College of American Pathologists Proficiency Testing ProgramSeminars in Thrombosis and Hemostasis, 2006
- An External Quality Assessment Program for von Willebrand Factor Laboratory Analysis: An Overview from the European Concerted Action on Thrombosis and Disabilities FoundationSeminars in Thrombosis and Hemostasis, 2006
- Heightened Interaction between Platelets and Factor VIII/von Willebrand Factor in a New Subtype of von Willebrand's DiseaseThe New England Journal of Medicine, 1980